Table 3 Previous antiangiogenic treatment details (N = 9).

From: Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

Patient Study line Antiangiogenic therapy before study Apatinib therapy in study line PFS
1 3 B + XELOX A 1.2
2 3 B + DOF A 3.6
3 3 B + D A + S 3
4 4 B + everolimus A + Iri 2.2
5 3 A A + S 3.6
6 3 A A + Iri 3.4
7 3 A A + X 8.6
8 3 A A + D 5.7
9 4 A A + O 1.8
  1. (A: apatinib; B: bevacizumab; XELOX: oxaliplatin and capecitabine; DOF: docetaxel, oxaliplatin, and fluorouracil; D: docetaxel; S: S-1; Iri: Irinotecan; X: capecitabine; O: oxaliplatin).